Research
Hormonal
Testosterone replacement therapy improves bone mineral density (BMD) and reduces fracture risk in hypogonadal men, with effects mediated by both androgen and estrogen receptors.
If you have low testosterone, you are at higher risk for osteoporosis and fractures. TRT can help build and maintain bone density, bringing it back to normal levels. This is a key benefit beyond just sexual health and muscle mass.
GoodSupportsHIGH confidence
Behre et al. (1997) and Zitzmann et al. (2002) clearly showed the beneficial effect of testosterone replacement therapy on BMD in hypogonadal men, with improvements over several years... The mechanism of action of androgens on bone is complex. Testosterone acts on both osteoblasts and osteoclasts via both androgen receptors and, following aromatization, via estrogen receptors.
Why this rating
Multiple studies cited show consistent BMD improvements, though the relative contribution of testosterone vs. estrogen is still debated.
Source
Testosterone replacement therapy: current trends and future directions
Eberhard Nieschlag et al. · Human Reproduction Update · 2004
DOI 10.1093/humupd/dmh035
narrative_reviewCited 224×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Testosterone replacement therapy (TRT) restores serum testosterone to normal ranges, thereby improving mood, energy, sexual function, lean body mass, erythropoiesis, and bone mineral density in hypogonadal men.Good
- Testosterone replacement therapy may have beneficial effects on cardiovascular health in men with coronary artery disease or chronic heart failure, improving exercise tolerance and vascular reactivity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →